

CLIENT:

# Consumer Product Testing Co.

### FINAL REPORT

Mizue Aikawa

Argo, Inc.

4-7-37-B203 Minamitanaka Nerima-ku, Tokyo 177-0035

Japan

SPONSOR: Sansho Cosme Inc.

2-14-20-3F Sumiyoshi Ikeda City, Osaka

Japan

TEST: Repeated Insult Patch Test

Protocol No.: 1.01

TEST MATERIAL: SAVONYS SUPER PROTECT

EXPERIMENT

REFERENCE NUMBER: C04

C04-0589.01

Richard R. Eisenberg, M.D. Board Certified Dermatologist

Mulus Exember

Michael Traudt, Ph.I.

Director, Clinical Evaluations

Joy Frank, R.N.

Executive Vice President, Clinical Evaluations

This report is submitted for the exclusive use of the person, declinerable, or corporation to whom it is addressed, and neither the report nor the name of these Laboratories nor any member or its staff, may be used in connection with the advertising or as a of any product or process without written authorization.



## QUALITY ASSURANCE UNIT STATEMENT

Study No.: C04-0589.01

The objective of the Quality Assurance Unit (QAU) is to monitor the conduct and reporting of clinical laboratory studies. These studies have been performed with adherence to the applicable ICH Guideline E6 for Good Clinical Practice and requirements provided for in 21 CFR parts 50 and 56 and in accordance to standard operating procedures and applicable protocols. The QAU maintains copies of study protocols and standard operating procedures and has inspected this study. All data pertinent to this study will be stored in the Consumer Product Testing Company archive, unless specified otherwise, in writing by the Sponsor.

#### Quality Assurance personnel involved:

Richard Hettenbach, M.A.

Date

Senior Director of Regulatory Affairs & Quality Assurance

The representative signature of the Quality Assurance Unit signifies that this study has been performed in accordance with standard operating procedures and study protocol as well as government regulations regarding such procedures and protocols.

Argo, Inc. C04-0589.01 Page 3

Objective:

To determine by repetitive epidermal contact the potential of a test material to induce primary or cumulative irritation and/or allergic contact sensitization.

Participants:

Fifty-six (56) qualified subjects, male and female, ranging in age from 16 to 78 years, were selected for this evaluation. Fifty-three (53) subjects completed this study. The remaining subjects discontinued their participation for various reasons, none of which were related to the application of the test material.

Inclusion Criteria:

- Male and female subjects, age 16<sup>n</sup> and over.
- Absence of any visible skin disease which might be confused with a skin reaction from the test material.
- Prohibition of use of topical or systemic steroids and/or antihistamines for at least seven days prior to study initiation.
- d. Completion of a Medical History form and the understanding and signing of an Informed Consent form.
- Considered reliable and capable of following directions.

Exclusion Criteria:

- a. Ill health:
- Under a doctor's care or taking medication(s) which could influence the outcome of the study.
- c. Females who are pregnant or nursing.
- A history of adverse reactions to cosmetics or other personal care products.

Test Material:

SAVONYS SUPER PROTECT

Study Schedule:

Panel # Initiation Date Completion Date

20040355 June 21, 2004 July 29, 2004

With parental or guardian consent

#### Methodology:

The upper back between the scapulae served as the treatment area. An amount sufficient to cover the contact surface, was applied to the 1" x 1" absorbent pad portion of a clear adhesive dressing\*. This was then applied to the appropriate treatment site to form a semi-occluded patch.

#### Induction Phase:

Patches were applied three (3) times per week (e.g., Monday, Wednesday, and Friday) for a total of nine (9) applications. The site was marked to ensure the continuity of patch application. Following supervised removal and scoring of the first Induction patch, participants were instructed to remove all subsequent Induction patches at home, twenty-four hours after application. The evaluation of this site was made again just prior to re-application. If a participant was unable to report for an assigned test day, one (1) makeup day was permitted. This day was added to the Induction period. It was noted that due to a holiday weekend which occurred during the Induction Phase, subjects who required a makeup day experienced a delay between applications.

With the exception of the first supervised Induction Patch reading, if any test site exhibited a moderate (2-level) reaction during the Induction Phase, application was moved to an adjacent area. Applications are discontinued for the remainder of this test phase, if a moderate (2-level) reaction was observed on this new test site. Applications would also be discontinued if marked (3-level) or severe (4-level) reactivity was noted.

Rest periods consisted of twenty-four hours following each Tuesday and Thursday removal, and forty-eight hours following each Saturday removal.

#### Challenge Phase:

Approximately two (2) weeks after the final Induction patch application, a Challenge patch was applied to a virgin test site adjacent to the original Induction patch site, following the same procedure described for Induction. The patch was removed and the site scored at the clinic twenty-four and seventy-two hours post-application.

<sup>\*</sup>Manufactured by TruMed Technologies, Inc., Burnsville, MN

Argo, Inc. C04-0589.01 Page 5

Evaluation Key:

0 = No visible skin reaction

= Barely perceptible or spotty crythema

1 = Mild crythema covering most of the test site

2 = Moderate erythema, possible presence of mild cdema

3 = Marked erythema, possible edema

4 Severe crythema, possible edema, vesiculation, bullae and/or

ulceration

Results:

The results of each participant are appended (Table 1).

Observations remained negative throughout the test interval.

Summary:

Under the conditions of this study, test material, SAVONYS SUPER PROTECT, did not indicate a potential for dermal irritation or allergic

contact sensitization.

Table 1 Panel #20040355

# Individual Results

## SAVONYS SUPER PROTECT

Subject		Induction Phase						Virgin Challenge Site				
Number	24*hr	1	2	3	4	5	6	7	8	9	24°hr	72 hr
1	0.	0	0	0	0	0	0	0	0 .	0	. 0	0
2	0	0	0	0	0	0	0	0	0	0	. 0	0
3	0.	0	0	0	0	0	0	0	0	0	0	0
4	0	0	. 0	0	0	0	0	0	0	0	. 0	0
5	0	0	0	0	0	0 -	0	0	0	0	0	0
6	0	0	0	0	0	0	. 0	0	0	0	0	0
7	0	0	0	0	0	0	0	.0	0	0	0	0
8	0	0	0	0	0	0	0	0	0	0	0	.0
9	0	.0	0	0	0	0	0	0	0	. 0	. 0	0
10	0.	0	0	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0	0	0	0
12	0	0	- 0	0	0	0	0	0	0	0	0	0
13	0	0	-			-DID N	OT CO	MPLET	ESTUE	Y		
14	0	0	0	0 -	0	0	0.	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	.0	0	0	0	0	.0
17	0	0	0	0	0	0	0	θ	0	Ò	0	0
18	0	0	0	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	.0	0	0	0	0	0
21.	0	0	0	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0	0	0	0
23	0	0	0	. 0	0	0	.0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0	. 0	0	0
25	. 0	0	0	0	0	0	0	. 0	0	0	0	0
26	0	0	0	0	0	0	0	0	.0	0	0	0
27	0	0	0	0	0	0	0	0	0	. 0	0.	0
28	0	0	0	0	0	0	.0	0	0	0	0	0

## Table 1 (continued) Panel #20040355

# Individual Results

# SAVONYS SUPER PROTECT

Subject		Induction Phase							Virgin Challeng Site			
Number	24°hr	1		3	4	_ 5	6	7_	8	9	24*hr	72 hr
29	0	0	0	. 0	0	0	0	0	0	0	0	0
30	0.	0	0	0	0	0	0	0	0	0	0	0
31	0	0	0	0 .	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0	0	0	0
34	0	0	. 0	0	0	0	0		DID NOT		ETE STUDY	
35	0	0	0	0	0 .	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	- 0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0	0	. 0	0
41	0	0	0	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0	Ó.	0	0
45	0 .	0.	0	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0	0	0	0
48	0		<del>.</del>		D	NO.	COMP	LETE S	TUDY-			
49	.0	0	0	0	0	0	0	0	0	0	0	0
50	0 .	0	0	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	. 0	0	0	0	0	. 0	0
52	0	0	0	0	0	0	. 0	0	0	0	0	0
53	0	0	. 0	0	0	0	. 0	0	0.	0	0	0
54	0	0	0	0	0	0 -	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0 -	0	0	0
56	0	0	. 0	0	0	0	. 0	0	0	0	0	0

Table 2 Panel #20040355

# Subject Data

	Subject		2.4	
- 1	Number	Initials	Age	Sex
		De	72	F
	1	DS	73	
	2	HS	76	M
		AM	72	F
	4	JM	77	M
	5	СВ	. 70	F
	6	AS	25	F
	7	EG	49	F
	. 8	TM	76	F
	9	PH	48	F
47	10	JG	22	F
	11	DP	44	F
	12	IP	52	F
	13	L	31	F
	14	CG		M
	15	EK	16	M
	16	RK	53	F
	17	JF	. 24	M
	18	BR	45 .	F
	19	LV	24	F
	20	MH	17	M
	21	PM	52	F
	22	SG	64	M
- 3	23	RC.	32	M
	24	PL	58	F
	25	DD	57	F
	26	LL	. 40	F
	27	AP	35	M
	28	TL	54	F
	2.17			

## Table 2 (continued) Panel #20040355

# Subject Data

Subject Number	Initials	Age	Sex
15 . 15			
29	HL .	18	M
30	JD	64	F
31	MW	42	F
32	NM	49	M
33	MT	50	M
34	TL	21	F
35	PG	44	M
36	ML	51	F
37	TP	63	F
38	MW	70	F
39	AT .	31	. M
40	FN	70	F
41	ES	71	F
42	LH	70	F
43	GB	51	F
44	AZ	75	F
45	FD	78	M
46	AL	76	F
47	JR	73	F
48	RA	66	M
49	DM	38	F
50	WB	43	M
51	MA	35	F
52	MO	67	F
53	YH	35	F
54	EL	19	M
55	JL	20	M
56	KM	56	F